Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial

Affiliations

• ¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10021, USA. [email protected].
• ² Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ³ Clinic for Urology, Clinic for Medical Oncology, University Hospital Essen, Essen, Germany.
• ⁴ Department of Urology and Department of Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
• ⁵ Department of Outpatient Chemotherapy, Prof. Franciszek Łukaszczyk Oncology Centre, Bydgoszcz, Poland.
• ⁶ Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Trust, Preston, UK.
• ⁷ Department of Medicine and Surgery, University of Parma, Parma, Italy.
• ⁸ Medical Oncology Unit, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
• ⁹ ICON Research, South Brisbane, and Queensland University of Technology, Brisbane, QLD, Australia.
• ¹⁰ Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
• ¹¹ Instituto Médico Río Cuarto, Río Cuarto, Argentina.
• ¹² Department of Surgery-Urology, CHUM-Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
• ¹³ Department of Cancer Medicine, Gustave Roussy, Villejuif, France.
• ¹⁴ Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
• ¹⁵ University of California, Los Angeles, Los Angeles, CA, USA.
• ¹⁶ Northwestern University Medical Center, Chicago, IL, USA.
• ¹⁷ Interdisciplinary Centre on Renal Tumors, University of Munich, Munich, Germany.
• ¹⁸ Hospital Universitario Lucus Augusti (HULA), EOXI de Lugo, Cervo e Monforte, Lugo, Spain.
• ¹⁹ Department of Global Biometrics and Data Science, Bristol Myers Squibb, Princeton, NJ, USA.
• ²⁰ Department of Oncology Late Clinical Global Drug Development, Bristol Myers Squibb, Princeton, NJ, USA.
• ²¹ Department of Oncology, Clinical Development, Bristol Myers Squibb, Princeton, NJ, USA.
• ²² Takeda Pharmaceuticals, Boston, MA, USA.
• ²³ Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
• ²⁴ Department of Urology, The Royal Free London NHS Foundation Trust, London, UK.
• ²⁵ Division of Surgery and Interventional Science, University College London, London, UK.